Any “savings” from hollowing out early childhood investment will only be deferred to the schoolhouses, courtrooms, emergency ...

Members of the Cornell Health Policy Insight Panel had mixed views on whether greater use of reference pricing would lower ...

Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...

Value-based care is conventionally classified as an alternative payment model. That classification mistakes the output for ...

The way to bring down the political temperature is to invest in the one sector where the return may be larger than the ...

If Congress shields self-insured plans from state regulation, it must ensure that federal oversight is strong enough to ...

Rob Lott and Irene Papanicolas examine how Americans pay for health care through taxes, premiums, and out-of-pocket costs, ...

In the early parallel years, hybrid rates ran 6.2 percentage points above digital-only rates in commercial plans and 9.3 ...

After a series of losses in constitutional challenges to the Medicare Drug Price Negotiation Program, the drug industry seems to be moving to challenging the program on statutory grounds.

Six pending federal bills would regulate private equity in health care, from an outright ban to disclosure, licensing, and antitrust tools. Rather than a categorical ban, federal policy makers could ...

From regulatory efforts to streamline approvals to emerging AI-driven decision-making, this episode explores the forces ...